Safety and Efficacy of VDPHL01 in Males and Females With AGA
An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia
In the register
The register attaches this trial to VDPHL-01 (oral minoxidil) (Veradermics), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 2
- Sponsor
- Veradermics, Inc.
- Participants (registry)
- 70
- Start
- July 2024
- Primary completion
- August 2026
- Study completion
- August 2026
- Last registry update
- November 2025
- Countries
- United States
Conditions studied: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01
Other trials of VDPHL-01 (oral minoxidil)
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Safety and Efficacy of VDPHL01 in Males With AGA
Efficacy and Safety of VDPHL01 in Males With AGA
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.